Prediabetes is Characterized by Higher FGF23 Levels and Higher Prevalence of Vitamin D Deficiency Compared to Normal Glucose Tolerance Subjects

Antoaneta Gateva; Yavor Assyov; Adelina Tsakova; Zdravko Kamenov

doi:10.1055/a-0813-3164

Hormone and Metabolic Research, Table of Contents

Horm Metab Res 2019; 51(02): 106-111
DOI: 10.1055/a-0813-3164

Endocrine Care

Prediabetes is Characterized by Higher FGF23 Levels and Higher Prevalence of Vitamin D Deficiency Compared to Normal Glucose Tolerance Subjects

Antoaneta Gateva

¹Department of Internal Medicine, Clinic of Endocrinology, University Hospital “Alexandrovska”, Medical University Sofia, Sofia, Bulgaria

,

Yavor Assyov

¹Department of Internal Medicine, Clinic of Endocrinology, University Hospital “Alexandrovska”, Medical University Sofia, Sofia, Bulgaria

,

Adelina Tsakova

²Department of Clinical Laboratory and Clinical Immunology, Central Clinical Laboratory, University Hospital “Alexandrovska”, Medical University Sofia, Sofia, Bulgaria

,

Zdravko Kamenov

¹Department of Internal Medicine, Clinic of Endocrinology, University Hospital “Alexandrovska”, Medical University Sofia, Sofia, Bulgaria

› Author Affiliations

Abstract

In the last years there is an increasing interest towards the bone as an endocrine organ and the role of bone and calcium-phosphate metabolism markers in a range of metabolic disturbances. The aim of the present study is to assess the changes of calcium phosphate metabolism markers in patients with prediabetes compared to normogycemic controls and their link to glucose disturbances and cardiovascular risk factors. In this study, 80 patients with mean age 50.4±10.6 years were included, divided into 2 age- and BMI-matched groups – group 1 with obesity without glycemic disturbances (n=41) and group 2 with obesity and prediabetes (n=39). Oral glucose tolerance test (OGTT) with measurement of immunoreactive insulin was performed in all participants and levels of PTH, 25(OH)D, FGF23, and Klotho were measured. We found significantly higher levels of FGF23 in patients with prediabetes compared to normal glucose tolerance subjects (10.4±10.7 vs. 5.8±7.3 pg/ml; p=0.03). FGF23 showed a weak positive correlation to fasting blood glucose (r=0.224; p=0.048) but not to blood glucose on the first and second hour of oral glucose tolerance test or insulin levels. There was extremely high prevalence of vitamin D deficiency in both groups. Lower levels of 25(OH)D were observed in prediabetes group, although without statistical significance (p=0.57). Patients with prediabetes have higher FGF23 levels and higher prevalence of vitamin D deficiency compared to normal glucose tolerance subjects. Elevated FGF23 levels seem to be correlated more to elevated fasting blood glucose levels than to insulin resistance state of the patients.

Key words

prediabetes - FGF23 - klotho - vitamin D - insulin resistance

Full Text

References

References
1 Gabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J, Bennett PH, Knowler WC. The 1997 american diabetes association and 1999 World health organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 2000; 23: 1108-1112
2 Shaw JE, Zimmet PZ, de Courten M, Dowse GK, Chitson P, Gareeboo H, Hemraj F, Fareed D, Tuomilehto J, Alberti KG. Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritus?. Diabetes Care 1999; 22: 399-402
3 de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population; The Hoorn study. JAMA 2001; 285: 2109-2113
4 Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith Jr SC. International diabetes federation task force on epidemiology and prevention; Hational heart, lung, and blood institute; American heart association; World heart federation; International atherosclerosis society; International association for the study of obesity.harmonizing the metabolic syndrome: A joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation; International Atherosclerosis society; and international association for the study of obesity. Circulation 2009; 120: 1640-1645
5 Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281
6 Alvarez JA, Ashraf A. Role of vitamin D in insulin secretion and insulin sensitivity for glucose homeostasis. Int J Endocrinol 2010; 351-385
7 Teegarden D, Donkin SS. Vitamin D: Emerging new roles in insulin sensitivity. Nutr Res Rev 2009; 22: 82-92
8 Parildar H, Cigerli O, Unal DA, Gulmez O, Demirag NG. The impact of Vitamin D Replacement on glucose metabolism. Pak J Med Sci 2013; 29: 1311-1314
9 Kuro M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45-51
10 Kuro M. Endocrine FGFs and Klothos: Emerging concepts. Trends Endocrinol Metab 2008; 19: 239-245
11 Kuro M. Overview of the FGF23-Klotho axis. Pediatr Nephrol 2010; 25: 583-590
12 Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, McGuinness OP, Chikuda H, Yamaguchi M, Kawaguchi H, Shimomura I, Takayama Y, Herz J, Kahn CR, Rosenblatt KP, Kuro M. Suppression of aging in mice by the hormone Klotho. Science 2005; 309: 1829-1833
13 Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444: 770-774
14 Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592
15 Mitani H, Ishizaka N, Aizawa T, Ohno M, Usui S, Suzuki T, Amaki T, Mori I, Nakamura Y, Sato M, Nangaku M, Hirata Y, Nagai R. In vivo klotho gene transfer ameliorates angiotensin II-induced renal damage. Hypertension 2002; 39: 838-843
16 Donate-Correa J, Mora-Fernández C, Martínez-Sanz R, Muros-de-Fuentes M, Pérez H, Meneses-Pérez B, Cazaña-Pérez V, Navarro-González JF. Expression of FGF23/KLOTHO system in human vascular tissue. Int J Cardiol 2013; 165: 179-183
17 Garimella PS, Ix JH, Katz R, Chonchol MB, Kestenbaum BR, de Boer IH, Siscovick DS, Shastri S, Hiramoto JS, Shlipak MG, Sarnak MJ. Fibroblast growth factor 23, the ankle-brachial index, and incident peripheral artery disease in the Cardiovascular Health Study. Atherosclerosis 2014; 233: 91-96
18 Jovanovich A, Ix JH, Gottdiener J, McFann K, Katz R, Kestenbaum B, de Boer IH, Sarnak M, Shlipak MG, Mukamal KJ, Siscovick D, Chonchol M. Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults. Atherosclerosis 2013; 231: 114-119
19 Heine GH, Seiler S, Fliser D. FGF-23: The rise of a novel cardiovascular risk marker in CKD. Nephrol Dial Transplant 2012; 27: 3072-3081
20 Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M. HOST Investigators. FGF-23 Associates with Death, cardiovascular events, and initiation of chronic dialysis. J Am SocNephrol 2011; 22: 1913-1922
21 Liu JJ, Liu S, Morgenthaler NG, Wong MD, Tavintharan S, Sum CF, Lim SC. Association of plasma soluble a-klotho with pro-endothelin-1 in patients with type 2 diabetes. Atherosclerosis 2014; 233: 415-418
22 Saito K, Ishizaka N, Mitani H, Ohno M, Nagai R. Iron chelation and a free radical scavenger suppress angiotensin II- induced downregulation of klotho, an anti-aging gene, in rat. FEBS Lett 2003; 551: 58-62
23 Zhang H, Li Y, Fan Y, Wu J, Zhao B, Guan Y, Chien S, Wang N. Klotho is a target gene of PPAR-gamma. Kidney Int 2008; 74: 732-739
24 Asai O, Nakatani K, Tanaka T, Sakan H, Imura A, Yoshimoto S, Samejima K, Yamaguchi Y, Matsui M, Akai Y, Konishi N, Iwano M, Nabeshima Y, Saito Y. Decreased renal alpha-klotho expression in early diabetic nephropathy in humans and mice and its possible role in urinary calcium excretion. Kidney Int 2012; 481: 539-547
25 Seiler S, Wen M, Roth HJ, Fehrenz M, Flügge F, Herath E, Weihrauch A, Fliser D, Heine GH. Plasma Klotho is not related to kidney function and does not predict adverse outcome in patients with chronic kidney disease. Kidney Int 2012; 83: 121-128
26 Arancibia C, Galgani J, Valderas JP, Morales M, Santos JL, Pollak F. Evaluation of serum insulin levels after an oral glucose load for the diagnosis of insulin resistance. Rev Med Chil 2014; 142: 1106-1112
27 Ascaso J, Pardo S, Real JT, Lorente RI, Priego A, Carmena R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 2003; 26: 3320-3325
28 Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM. Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1911-1930
29 Hyppönen E, Läärä E, Reunanen A, Järvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: A birth-cohort study. Lancet 2001; 358: 1500-1503
30 Pittas AG, Sun Q, Manson JE, Dawson-Hughes B, Hu FB. Plasma 25-hydroxyvitamin D concentration and risk of incident type 2 diabetes in women. Diabetes Care 2010; 33: 2021-2023
31 Scragg R, Sowers M, Bell C. Third National H, Nutrition examination survey. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the third national health and nutrition examination survey. Diabetes Care 2004; 27: 2813-2818
32 Liu E, Meigs JB, Pittas AG, Economos CD, McKeown NM, Booth SL, Jacques PF. Predicted 25-hydroxyvitamin D score and incident type 2 diabetes in the Framingham offspring study. Am J Clin Nutr 2010; 91: 1627-1633
33 Mitri J, Muraru MD, Pittas AG. Vitamin D and type 2 diabetes: A systematic review. Eur J Clin Nutr 2011; 65: 1005-1015
34 Khan H, Kunutsor S, Franco OH, Chowdhury R. Vitamin D, type 2 diabetes and other metabolic outcomes: A systematic review and meta-analysis of prospective studies. Proc Nutr Soc 2013; 72: 89-97
35 Karras SN, Anagnostis P, Antonopoulou V, Tsekmekidou X, Koufakis T, Goulis DG, Zebekakis P, Kotsa K. The combined effect of vitamin D and parathyroid hormone concentrations on glucose homeostasis in older patients with prediabetes: A cross-sectional study. Diab Vasc Dis Res 2018; 15: 150-153
36 Banerjee A, Khemka VK, Roy D, Poddar J, Roy TKS, Karnam S. Role of serum adiponectin and vitamin d in prediabetes and diabetes mellitus. Can J Diabetes 2017; 41: 259-265
37 Kwon HN, Lim H. Relationship between serum vitamin D status and metabolic risk factors among korean adults with prediabetes. PLoS One 2016; 11: e0165324
38 Dutta D, Maisnam I, Shrivastava A, Sinha A, Ghosh S, Mukhopadhyay P, Mukhopadhyay S, Chowdhury S. Serum vitamin-D predicts insulin resistance in individuals with prediabetes. Indian J Med Res 2013; 138: 853-860
39 Al Masri M, Romain AJ, Boegner C, Maimoun L, Mariano-Goulart D, Attalin V, Leprieur E, Picandet M, Avignon A, Sultan A. Vitamin D status is not related to insulin resistance in different phenotypes of moderate obesity. Appl Physiol Nutr Metab 2017; 42: 438-442
40 Tsakova A, Gateva A, Kamenov Z. 25(OH) vitamin D levels in premenopausal women with polycystic ovary syndrome and/or obesity. Int J Vitamin Nutr Res 2012; 82: 399-404
41 Alvarez JA, Ashraf A. Role of vitamin d in insulin secretion and insulin sensitivity for glucose homeostasis. Int J Endocrinol 2010; 351385
42 Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592
43 Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011; 22: 1913-1922
44 Titan SM, Zatz R, Graciolli FG, dos Reis LM, Barros RT, Jorgetti V, Moyses RM. FGF-23 as a predictor of renal outcome in diabetic nephropathy. Clin J Am Soc Nephrol 2011; 6: 241-247
45 Ix JH, Shlipak MG, Wassel CL, Whooley MA. Fibroblast growth factor-23 and early decrements in kidney function: The Heart and Soul Study. Nephrol Dial Transplant 2010; 25: 993-997
46 Wahl P, Xie H, Scialla J, Anderson CA, Bellovich K, Brecklin C, Chen J, Feldman H, Gutierrez OM, Lash J, Leonard MB, Negrea L, Rosas SE, Anderson AH, Townsend RR, Wolf M, Isakova T. Chronic renal insufficiency cohort study group. earlier onset and greater severity of disordered mineral metabolism in diabetic patients with chronic kidney disease. Diabetes Care 2012; 35: 994-1001
47 Vervloet MG, van Zuilen AD, Heijboer AC, ter Wee PM, Bots ML, Blankestijn PJ, Wetzels JF. MASTERPLAN group study. Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: an analysis of the MASTERPLAN cohort. BMC. Nephrol 2012; 13: 20
48 Schoppet M, Hofbauer LC, Brinskelle-Schmal N, Varennes A, Goudable J, Richard M, Hawa G, Chapurlat R, Szulc P. Serum level of the phosphaturic factor FGF23 is associated with abdominal aortic calcification in men: The STRAMBO study. J Clin Endocrinol Metab 2012; 97: E575-E583
49 Hu X, Ma X, Luo Y, Xu Y, Xiong Q, Pan X, Bao Y, Jia W. Elevation in fibroblast growth factor 23 and its value for identifying subclinical atherosclerosis in first-degree relatives of patients with diabetes. Sci Rep 2016; 6: 34696
50 Fajol A, Chen H, Umbach AT, Quarles LD, Lang F, Föller M. Enhanced FGF23 production in mice expressing PI3K-insensitive GSK3 is normalized by β-blocker treatment. FASEB J 2016; 30: 994-1001